Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

71.97 USD +0.04 (+0.06%)
Official Closing Price Updated: 7:00 PM EDT, Sep 21, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 11,995,917
Open 72.48
Bid (Size) 71.79 (2)
Ask (Size) 71.97 (5)
Prev. Close 71.93
Today's Range 71.77 - 72.68
52wk Range 15.32 - 85.60
Shares Outstanding 2,531,374,696
Dividend Yield 3.61%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
New Cancer Therapies Continue to Develop and Give Hope in Rapidly Improving Oncology Space
FN Media Group Presents USA News Group News Commentary 
From PR Newswire
New Cancer Therapies Continue to Develop and Give Hope in Rapidly Improving Oncology Space
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert

Performance

YTD
-11.10%
-11.10%
1 Month
-8.18%
-8.18%
3 Month
-5.54%
-5.54%
6 Month
-5.64%
-5.64%
1 Year
-13.42%
-13.42%

More News

Read More
Celebrating the Diversity of Our Workforce
Tags Diversity & Inclusion Merck NYSE:MRK
From 3BL Media: Corporate Social Responsibility, Energy and Health News
9 Health Care Stocks Showing Unusual Options Activity In Today's Session
Tags SDC Benzinga CRVS
From Benzinga
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Reduced Risk of Death by 27% Versus Chemotherapy as First-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer Whose Tumors Exp
From Business Wire News Releases
Thinking about trading options or stock in Draftkings, Merck, ConocoPhillips, Walgreens Boots Alliance, or MGM Resorts?
From PR Newswire
Apple And Disney Lead The Dow Jones Lower
Tags QQQ News DIA
From Benzinga
Merck’s KEYTRUDA® (pembrolizumab) Demonstrated Superior Recurrence-Free Survival (RFS) in Patients With Resected High-Risk Stage II Melanoma Compared to Placebo in the Adjuvant Setting
From Business Wire News Releases
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Death by One-Third Versus Chemotherapy With or Without Bevacizumab as First-Line Treatment for Persisten
From Business Wire News Releases
These 3 Dow Stocks Are Set to Soar in 2021's Second Half and Beyond
Tags HD DIS Market News
From Motley Fool
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy for Certain Patients With Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Can
From Business Wire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.